GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GT Biopharma Inc (NAS:GTBP) » Definitions » PB Ratio

GT Biopharma (GT Biopharma) PB Ratio : 0.93 (As of Jun. 03, 2024)


View and export this data going back to . Start your Free Trial

What is GT Biopharma PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-06-03), GT Biopharma's share price is $3.565. GT Biopharma's Book Value per Share for the quarter that ended in Mar. 2024 was $3.85. Hence, GT Biopharma's PB Ratio of today is 0.93.

The historical rank and industry rank for GT Biopharma's PB Ratio or its related term are showing as below:

GTBP' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 22.26
Current: 0.93

During the past 13 years, GT Biopharma's highest PB Ratio was 22.26. The lowest was 0.00. And the median was 0.00.

GTBP's PB Ratio is ranked better than
82.33% of 1313 companies
in the Biotechnology industry
Industry Median: 2.52 vs GTBP: 0.93

During the past 12 months, GT Biopharma's average Book Value Per Share Growth Rate was -63.80% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of GT Biopharma was 88.60% per year. The lowest was -43.90% per year. And the median was 22.35% per year.

Back to Basics: PB Ratio


GT Biopharma PB Ratio Historical Data

The historical data trend for GT Biopharma's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GT Biopharma PB Ratio Chart

GT Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 4.46 2.47 1.41

GT Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.55 1.08 1.00 1.41 1.15

Competitive Comparison of GT Biopharma's PB Ratio

For the Biotechnology subindustry, GT Biopharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GT Biopharma's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GT Biopharma's PB Ratio distribution charts can be found below:

* The bar in red indicates where GT Biopharma's PB Ratio falls into.



GT Biopharma PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

GT Biopharma's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2024)
=3.565/3.847
=0.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


GT Biopharma  (NAS:GTBP) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


GT Biopharma PB Ratio Related Terms

Thank you for viewing the detailed overview of GT Biopharma's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


GT Biopharma (GT Biopharma) Business Description

Traded in Other Exchanges
Address
8000 Marina Boulevard, Suite 100, Brisbane, CA, USA, 94005
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
Executives
Charles J Casamento director 99 BELBROOK WAY, ATHERTON CA 94027
Michael Martin Breen director, officer: Exec. Chair. and Interim CEO LOWSLEY HOUSE 133 HEADLEY ROAD, LIPHOOK X0 GU30 7PU
Manu Ohri officer: CFO & Secretary 2355 MAIN STREET, SUITE 120, IRVINE CA 92614
Bruce Wendel director 70 ELEVEN O'CLOCK ROAD, WESTON CT 06883
Gregory Berk officer: Pres. of R&D, CMO HANA BIOSCIENCES, INC., 400 OYSTER POINT BLVD, SAN FRANCISCO CA 94080
Shrotriya Rajesh C Md director 157 TECHNOLOGY DRIVE, IRVINE CA 92618
Alan Louis Urban director 1524 CLOVERFIELD BOULEVARD, SUITE E, SANTA MONICA CA 90404
Gavin Choy officer: Acting Chief Financial Officer 8000 MARINA BLVD, STE. 100, C/O GT BIOPHARMA, INC., BRISBANE CA 94005
Steven W Weldon director, officer: CFO 7280 WESTPOINTE BLVD, APT 831, ORLANDO FL 32835
Shawn Cross director, officer: Chief Executive Officer 1825 K STREET SUITE 510, WASHINGTON DC 20006
Raymond W. Urbanski officer: Chief Medical Officer 28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Kathleen Clarence-smith director, 10 percent owner, officer: CEO 1623 31ST STREET NW, WASHINGTON DC 20007
Mark J Silverman 10 percent owner 224 22ND ST., SANTA MONICA CA 90402
Bristol Capital Llc 10 percent owner
Bristol Investment Fund Ltd 10 percent owner 89 NEXUS WAY, CAMANA BAY, PO BOX 311063, GRAND CAYMAN E9 KY1-1205

GT Biopharma (GT Biopharma) Headlines

From GuruFocus

GT Biopharma Appoints Manu Ohri as Chief Financial Officer

By PRNewswire PRNewswire 02-18-2022